Targeting of PARP has been shown to kill cancer cells deficient in the homologous recombination factors breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) (see below), paving the way for the use of PARP inhibitors in clinical practice 44, 45. The gene discussed is PARP1; the disease is cancer.